Premium
The Effect of Encapsulated, Low‐Dose Colestipol in Patients with Hyperlipidemia
Author(s) -
Linet Otto I.,
Grzegorczyk Cynthia R.,
Demke Donald M.
Publication year - 1988
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1988.tb03219.x
Subject(s) - medicine , hyperlipidemia , palatability , gastroenterology , constipation , endocrinology , pathology , diabetes mellitus
Colestipol is an effective cholesterol (C)‐loivering agent, but it must be taken in large doses and the palatability is poor. In an open‐label study, the effects of low doses (2–10 g) of encapsulated colestipol (size: 1 g or 0.65 g) were investigated. There were 16 men and 16 women with an average age of 59 ± 11 years and with hyperlipidemias IIA, IIB, or IV. Patients were on AHA I diet and stayed in the study for up to 2 years with regular follow‐up every 3 to 4 months. Colestipol was started after several months of dietary baseline; it was tolerated well with only two patients reporting mild constipation. A group mean for total cholesterol (T‐C), LDL‐C, HDL‐C, VLDL‐C and triglycerides (TG) was calculated at each of four daily dose intervals, i.e., 2 to 4 g, 4 to 6 g, 6 to 8 g and 8 to 10 g. Each patient usually received more than one of the four dosage intervals. A paired t test and a rank sum test were performed to test for significant (P ≤ .05) differences between baseline and drug treatment. With the exception of the lowest dose, total C was significantly decreased by all dosage ranges and LDL‐C changes were similar. There was no significant effect on HDL‐C and VLDL‐C whereas TG levels increased at 4 to 6 g and 8 to 10 g dose. The use of diet and low colestipol doses may be considered in patients with moderate hypercholesterolemia who do not respond to diet alone.